Evidence map›Paper›PMID 37104709›Full record

ArticleJMIR research protocols2023

Characterizing Symptoms and Identifying Biomarkers of Long COVID in People With and Without HIV: Protocol for a Remotely Conducted Prospective Observational Cohort Study.

Nuria Gallego Márquez, Armaan Jamal, Rowena Johnston, E India Richter, Pamina M Gorbach, Tracy D Vannorsdall, Leah H Rubin, Cheryl Jennings, Alan L Landay, Michael J Peluso and 1 more

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Nuria Gallego Márquez *Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID https://orcid.org/0000-0002-0459-8738
Armaan Jamal *Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID https://orcid.org/0000-0002-9540-5179
Rowena JohnstonamfAR, The Foundation for AIDS Research, New York, NY, United States.ORCID https://orcid.org/0000-0002-5027-737X
E India RichterDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, United States.ORCID https://orcid.org/0000-0002-1717-4088
Pamina M GorbachDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, United States.ORCID https://orcid.org/0000-0003-2100-7765
Tracy D VannorsdallDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID https://orcid.org/0000-0003-3103-1371
Leah H RubinDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID https://orcid.org/0000-0003-2749-6328
Cheryl JenningsDepartment of Internal Medicine, Rush University Medical College, Chicago, IL, United States.ORCID https://orcid.org/0009-0002-3508-5350
Alan L LandayDepartment of Internal Medicine, Rush University Medical College, Chicago, IL, United States.ORCID https://orcid.org/0000-0001-9645-1356
Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, California, CA, United States.ORCID https://orcid.org/0000-0003-0585-6230
Annukka A R AntarDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID https://orcid.org/0000-0002-6775-1103
Johns Hopkins University · USRush University Medical Center · USUniversity of California, Los Angeles · USAmerican Foundation for AIDS Research · USUniversity of California System · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
The HIV Latent Reservoir, Suboptimal Immune Response on Antiretroviral Therapy, and Exogenous Cytokine TherapiesK08AI143391 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ANTAR, ANNUKKA AIDA ROSE · 2019 to 2023
$994k
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
NIAID NIH HHS K08 AI143391NIAID NIH HHS K23 AI157875NIAID NIH HHS L30 AI147159NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

backgroundLiving with HIV is a risk factor for severe acute COVID-19, but it is unknown whether it is a risk factor for long COVID.

objectiveThis study aims to characterize symptoms, sequelae, and cognition formally and prospectively 12 months following SARS-CoV-2 infection in people living with HIV compared with people without HIV. People with no history of SARS-CoV-2 infection, both with and without HIV, are enrolled as controls. The study also aims to identify blood-based biomarkers or patterns of immune dysregulation associated with long COVID.

methodsThis prospective observational cohort study enrolled participants into 1 of the following 4 study arms: people living with HIV who had SARS-CoV-2 infection for the first time <4 weeks before enrollment (HIV+COVID+ arm), people without HIV who had SARS-CoV-2 infection for the first time within 4 weeks of enrollment (HIV-COVID+ arm), people living with HIV who believed they never had SARS-CoV-2 infection (HIV+COVID- arm), and people without HIV who believed they never had SARS-CoV-2 infection (HIV-COVID- arm). At enrollment, participants in the COVID+ arms recalled their symptoms, mental health status, and quality of life in the month before having SARS-CoV-2 infection via a comprehensive survey administered by telephone or on the web. All participants completed the same comprehensive survey 1, 2, 4, 6, and 12 months after post-acute COVID-19 symptom onset or diagnosis, if asymptomatic, (COVID+ arms) or after enrollment (COVID- arms) on the web or by telephone. In total, 11 cognitive assessments were administered by telephone at 1 and 4 months after symptom onset (COVID+ arms) or after enrollment (COVID- arms). A mobile phlebotomist met the participants at a location of their choice for height and weight measurements, orthostatic vital signs, and a blood draw. Participants in the COVID+ arms donated blood 1 and 4 months after COVID-19, and participants in the COVID- arms donated blood once or none. Blood was then shipped overnight to the receiving study laboratory, processed, and stored.

resultsThis project was funded in early 2021, and recruitment began in June 2021. Data analyses will be completed by summer 2023. As of February 2023, a total of 387 participants were enrolled in this study, with 345 participants having completed enrollment or baseline surveys together with at least one other completed study event. The 345 participants includes 76 (22%) HIV+COVID+, 121 (35.1%) HIV-COVID+, 78 (22.6%) HIV+COVID-, and 70 (20.3%) HIV-COVID- participants.

conclusionsThis study will provide longitudinal data to characterize COVID-19 recovery over 12 months in people living with and without HIV. Additionally, this study will determine whether biomarkers or patterns of immune dsyregulation associate with decreased cognitive function or symptoms of long COVID. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/47079.

Indexed as

COVID-19HIVlong COVIDpost–acute COVID-19 syndromepostacute sequelae of SARS-CoV-2 infectionprospective observational cohort studyremote participationremote studySARS-CoV-2

Identifiers

PMID37104709
PMCPMC10234419
OpenAlexW4367187612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.